A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
Price : $35 *
At a glance
- Drugs Afatinib (Primary)
- Indications Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Aug 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2017 Results published in the Anticancer Research
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting as per results published in the Anticancer Research.